Maximum Fidelity Surgical Simulations Raises $2.25 Million in Seed Funding Round
Maximum Fidelity Surgical Simulations (MaxFi), founded in 2014 by Joss Fernandez, MD, FACS, is a company that provides lifelike cadavers for highly realistic surgical simulations in medical education, research, and military training. The companys patented and proprietary cadaver perfusion system allows cadavers to simulate physiological conditions like bleeding, breathing, and handling like live patients. MaxFis simulations are utilized by healthcare professionals, military medical personnel, and medical device manufacturers for realistic operating room and trauma care experience, research, and new product testing.
The recently completed seed funding round raised $2.25 million and will be used by MaxFi to build a stateoftheart medical device development and surgical simulation center in St. Louis. The center will provide clients with the most realistic surgical scenarios using lifelike cadavers. In addition, the funds will support the hiring of fulltime employees, development and launch of new technology, and expansion into new markets.
The funding round was led by investors St. Louis Arch Angels, BioGenerator Ventures, and Missouri Technology Corporation (MTC). St. Louis Arch Angels President Brian Kinman expressed confidence in MaxFis potential to advance healthcare and enhance St. Louis reputation as a leader in the industry. BioGenerator Managing Director Crystal Winkeler highlighted the strong market demand for MaxFis unique surgical simulation services, while MTC Executive Director Jack Scatizzi mentioned the companys alignment with MTCs mission of supporting highgrowth potential ventures in Missouri through equitybased funding.
Other investors in the seed funding round included Johnson & Johnson, Washington University in St. Louis, and Safeguard Medical. These partnerships underscore the growing demand for MaxFis simulations and the impact they have on patient care, medical education, and device innovation.
Additionally, MaxFi CEO Bob Mills expressed gratitude to the investors for enabling the company to scale operations, meet increasing demand, and continue making discoveries that save lives and advance medical practice.
Article